Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Lymphoma: highlights at ASH 2020

Amitkumar Mehta • 9 Dec 2020
ASH 2020
Diffuse Large B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Antibodies Axicabtagene ciloleucel CAR-T Mosunetuzumab Tisagenlecleucel
ELARA ZUMA-5

Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, shares his thoughts on updates in the field of lymphoma as presented at ASH 2020. Dr Mehta highlights promising early data from studies investigating bispecific antibodies such as mosunetuzumab both with and without chemotherapy, as well as advances in chimeric antigen receptor (CAR) T-cell therapy and results from the ZUMA-5 (NCT03105336) and ELARA trials. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Amitkumar Mehta

2:42
Interim results of an anti-SIRPα antibody, CC-95251, in R/R NHL
Amitkumar Mehta • 22 Dec 2021
2:57
Lymphoma highlights from ASH 2021
Amitkumar Mehta • 22 Dec 2021
3:21
CITADEL-205: Parsaclisib in R/R MCL
Amitkumar Mehta • 22 Dec 2021
3:00
Preliminary results of lemzoparlimab, an anti-CD47 antibody in R/R NHL
Amitkumar Mehta • 22 Dec 2021

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals